{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T09:28:02Z","timestamp":1776763682270,"version":"3.51.2"},"reference-count":15,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2024,4,17]]},"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:p>Bartter syndrome is a genetic disorder characterised by chloride-unresponsive metabolic alkalosis, hypokalaemia, hypomagnesaemia and hypercalciuria. While it commonly presents antenatally or in early infancy, sometimes, drugs can induce a state similar to Bartter syndrome in any age group, called acquired Bartter syndrome. Polymyxins and aminoglycosides are the most commonly implicated drugs. Polymyxin B and polymyxin E (popularly known as colistin) are the two chemically similar polymyxins that are commonly used clinically. While colistin is frequently associated with nephrotoxicity, polymyxin B is generally considered less nephrotoxic. This difference is due to the way these two drugs are handled by the kidneys. In this case report, we discuss a middle-aged male who developed Bartter syndrome due to polymyxin B, which resolved on discontinuation of the drug, and re-appeared after its re-introduction later. This case exemplifies the nephrotoxicity caused by polymyxin B and the need for vigilance when using this drug.<\/jats:p>","DOI":"10.1136\/bcr-2023-255242","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T11:20:10Z","timestamp":1714735210000},"page":"e255242","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Polymyxin B-induced Bartter syndrome"],"prefix":"10.1136","volume":"17","author":[{"given":"Bhavesh","family":"Mohan Lal","sequence":"first","affiliation":[{"name":"Department of Medicine, All India Institute of Medical Sciences, New Delhi, Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nimisha","family":"Musthafa Hafeesa","sequence":"additional","affiliation":[{"name":"Department of Medicine, All India Institute of Medical Sciences, New Delhi, Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naval Kishore","family":"Vikram","sequence":"additional","affiliation":[{"name":"Department of Medicine, All India Institute of Medical Sciences, New Delhi, Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7498-9112","authenticated-orcid":false,"given":"Animesh","family":"Ray","sequence":"additional","affiliation":[{"name":"Department of Medicine, All India Institute of Medical Sciences, New Delhi, Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,5,3]]},"reference":[{"key":"2025082801484410000_17.5.e255242.1","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.kint.2020.10.035","article-title":"Diagnosis and management of bartter syndrome: executive summary of the consensus and recommendations from the European rare kidney disease reference network working group for tubular disorders","volume":"99","author":"Konrad","year":"2021","journal-title":"Kidney Int"},{"key":"2025082801484410000_17.5.e255242.2","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-200503000-00007"},{"key":"2025082801484410000_17.5.e255242.3","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-232630","article-title":"Colistin-induced acquired bartter-like syndrome: an unusual cause of meltdown","volume":"13","author":"Tabish","year":"2020","journal-title":"BMJ Case Rep"},{"key":"2025082801484410000_17.5.e255242.4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/0886022X.2013.832861","article-title":"Acquired bartter-like syndrome association with netilmicin therapy in an extremely low birth weight infant","volume":"36","author":"Sandal","year":"2014","journal-title":"Ren Fail"},{"key":"2025082801484410000_17.5.e255242.5","doi-asserted-by":"crossref","DOI":"10.1007\/s40800-017-0052-1","article-title":"Reversible hypokalemia and bartter-like syndrome during prolonged systemic therapy with colistimethate sodium in an adult patient","volume":"4","author":"Kamal Eldin","year":"2017","journal-title":"Drug Saf Case Rep"},{"key":"2025082801484410000_17.5.e255242.6","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2015.1093933."},{"key":"2025082801484410000_17.5.e255242.7","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu213"},{"key":"2025082801484410000_17.5.e255242.8","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit453"},{"key":"2025082801484410000_17.5.e255242.9","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.4103\/1319-2442.301185","article-title":"Acquired bartter syndrome in primary sj\u00f6gren syndrome","volume":"31","author":"Fraj","year":"2020","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"2025082801484410000_17.5.e255242.10","doi-asserted-by":"crossref","first-page":"150","DOI":"10.5414\/CN109820","article-title":"From Bartter\u2019s syndrome to renal tubular acidosis in a patient with hashimoto\u2019s thyroiditis: a case report","volume":"94","author":"Wang","year":"2020","journal-title":"Clin Nephrol"},{"key":"2025082801484410000_17.5.e255242.11","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfn600"},{"key":"2025082801484410000_17.5.e255242.12","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01705-13"},{"key":"2025082801484410000_17.5.e255242.13","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jcf.2019.08.027","article-title":"Pharmacokinetics of colistin after nebulization or intravenous administration of colistin methanesulphonate (Colimycin\u00ae) to cystic fibrosis patients","volume":"19","author":"Magr\u00e9ault","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2025082801484410000_17.5.e255242.14","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.373","article-title":"Improving the assessment of adverse drug reactions using the naranjo algorithm in daily practice: the Japan adverse drug events study","volume":"6","author":"Murayama","year":"2018","journal-title":"Pharmacol Res Perspect"},{"key":"2025082801484410000_17.5.e255242.15","unstructured":"The use of the WHO-UMC system for standardised case causality assessment. n.d. Available: https:\/\/www.who.int\/publications\/m\/item\/WHO-causality-assessment"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2023-255242","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T08:48:54Z","timestamp":1756370934000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2023-255242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":15,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5,3]]},"published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1136\/bcr-2023-255242"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2023-255242","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5]]}}}